The Viet Nam Competition Authority eyed the nation’s pharmaceutical sector at a recent conference, where the regulator addressed the seeming paradox of a low concentration rate but increasing pharmaceutical companies. Reports say the head of the regulator’s Competition Supervision and Management Department spoke about the troublesome pattern of rising prices in the industry, despite the fact that there are nine times more distributors of pharmaceuticals than there are producers – a figure that implies a low concentration rate, usually associated with high competition and lower prices. Tran Phuong Lan stated that merger and acquisition activity could potentially increase competition by allowing foreign rivals into the market.
Featured News
Kimberly-Clark Seeks EU Antitrust Approval for Kenvue Takeover
Aug 26, 2026 by
CPI
UK Competition Watchdog Opens Formal Review of Brink’s $6.6 Billion NCR Atleos Acquisition
Aug 26, 2026 by
CPI
Trump Weighs Beef Deregulation Amid Meatpacking Antitrust Scrutiny
Aug 26, 2026 by
CPI
Meta Reaches $16.68 Billion Deal With US States Over Social-Media Risks
Aug 26, 2026 by
CPI
Teva Faces New Antitrust Scrutiny in Turkey Over Copaxone Patents
Aug 26, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Antipasto
Aug 24, 2026 by
CPI
“Anti-Monopoly” Antitrust Enforcement: Lessons Learned from the Biden Administration
Aug 24, 2026 by
Diana L. Moss
FTC v. Meta: The Importance of Quantitative Evidence in Antitrust
Aug 24, 2026 by
Dennis Carlton, John A. List, Allan Shampine, Hal Sider & Theresa Sullivan
Competitor Information Exchanges: Reducing Market Uncertainty Is What Matters, Not Level Of Detail
Aug 24, 2026 by
Kasia Czapracka, Assimakis Komninos, James Killick & Nina Frie
When Politics Meets Merger Control: 10 Transatlantic Takeaways
Aug 24, 2026 by
Rachel Brandenburger